Understanding how numerous actin-binding proteins (ABPs) work in concert to control the assembly, organization, and turnover of the actin cytoskeleton requires quantitative information about the levels of each component. Here, we measured the cellular concentrations of actin and the majority of the conserved ABPs in Saccharomyces cerevisiae, as well as the free (cytosolic) fractions of each ABP. The cellular concentration of actin is estimated to be 13.2 µM, with approximately two-thirds in the F-actin form and one-third in the G-actin form. Cellular concentrations of ABPs range from 12.4 to 0.85 µM (Tpm1> Pfy1> Cof1> Abp1> Srv2> Abp140> Tpm2> Aip1> Cap1/2> Crn1> Sac6> Twf1> Arp2/3> Scp1). The cytosolic fractions of all ABPs are unexpectedly high (0.6-0.9) and remain so throughout the cell cycle. Based on these numbers, we speculate that F-actin binding sites are limited in vivo, which leads to high cytosolic levels of ABPs, and in turn helps drive the rapid assembly and turnover of cellular F-actin structures.

31 Aug 2011·The EMBO JournalQ1 · BIOLOGY

The road not taken: new destinations for yeast mRNAs on the move

Q1 · BIOLOGY

Article

Author: Twiss, Jeffery L ; Yoo, Soonmoon

A review.Highly specific and precise mechanisms have evolved for transport of mRNAs to subcellular regions in polarized eukaryotic cells.RNA localization is largely thought to be driven by RNA structures that are recognized by RNA-binding proteins.In this issue of The EMBO Journal, Kilchert and Spang (2011) show that yeast ABP140 mRNA is localized through a translation-dependent mechanism.The first 17 amino acids of the nascent ABP140 peptide chain confer this activity.Much attention has been directed to mRNAs moving into the budding daughter cell of yeast.ABP140 mRNA goes the wrong way, localizing the mother cell's pole opposite to the bud.Moreover, the cotranslational localization motif in the ABP140 N terminus is able to overcome RNA structure-driven transport.This provides a novel mechanism to target mRNAs to subcellular sites that may be shared by other mRNAs that pave routes to previously unrecognized destinations.

100 Deals associated with ABP-140

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Preclinical	United States	Abpro Corp.	-
Prostatic Cancer	Preclinical	United States	Abpro Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ABP-140

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation